VC fund profile · evidence-aware directory data
OrbiMed stages, portfolio and investment profile
OrbiMed is a global healthcare investment firm spanning venture capital, growth equity, public equities and royalty/credit strategies. On October 15, 2026 it announced approximately $3B of commitments across Private Investments X (over $1.9B, US/European life-sciences VC) and Asia Partners VI (over $1B, Asian healthcare venture/growth). These are two distinct vehicles, not a single fund or startup round.
Keep track of OrbiMed
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$100K–$1M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Not recorded
Participates: Not recorded
Sector focus
healthtech · biotech-life-sciences
Geography
New York, United States
Founded Not recorded
Fund size / AUM
Over $21B firmwide, as disclosed October 15, 2026; includes strategies beyond these two funds.
A separate fund-size evidence record is not yet available.
Portfolio in our directory
None yet
Linked startup profiles
Latest fund vehicle
Not recorded
Vehicle name, size, and vintage are not yet structured.
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
Rounds they lead
Rounds they invest
Last verified: 2026-10-15T22:08:45Z. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.